Vertex Pharmaceuticals Incorporated VRTX
526.19
3.81
0.73%
as of 25 Sep
- Market cap
- $132.3B
- P/E
- 30.4×
Follow VRTX
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Vertex Pharmaceuticals Incorporated (VRTX) P/E ratio
As of 25 September 2026, Vertex Pharmaceuticals Incorporated (VRTX) trades at a P/E ratio of 30.4×. Over the past ten years it has ranged from 0.0× (June 2025) to 194× (October 2017); the current reading is higher than 74% of that period. That is above the Biotechnology industry median of 7.9× and above the Healthcare sector median of 22.7×.
P/E ratio, daily
Annual
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 29.3× | — |
| FY2024 | 0.0× | — |
| FY2023 | 29.3× | 32.82% |
| FY2022 | 22.0× | (8.69%) |
| FY2021 | 24.1× | 6.40% |
| FY2020 | 22.7× | (52.66%) |
| FY2019 | 47.9× | 138.24% |
| FY2018 | 20.1× | (85.93%) |
| FY2017 | 143× | — |
| FY2016 | 0.0× | — |
Quarterly
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 28.7× | 9.19% |
| Mar 2026 | 26.3× | (10.42%) |
| Dec 2025 | 29.3× | 7.23% |
| Sep 2025 | 27.3× | (13.20%) |
| 42 more quarters | Free account |
Against its own ten years
Low 0.0×
High 194×
Ten-year median
24.9×
Current reading's percentile
74
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| INSM Insmed, Inc. compare | n/m |
| RVMD Revolution Medicines, Inc. compare | n/m |
| MRNA Moderna, Inc. compare | n/m |
| REGN Regeneron Pharmaceuticals, Inc. compare | 18.8× |
| VRTX Vertex Pharmaceuticals Incorporated | 30.4× |
| ARGX argenex SE compare | 34.6× |
| RPRX Royalty Pharma PLC compare | 40.1× |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 43.6× |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 61.2× |
| Biotechnology industry median | 7.9× |
| Healthcare sector median | 22.7× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)
More on VRTX
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement